Recorded device evidence

Nextra CH Cannulated Hammertoe System (K221610): indications, design and recorded evidence

The acquired K221610 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 108 selected decisions under primary code HWC. 108 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

Calendar elapsed days: lower quartile 59.0, median 103.5, upper quartile 190.2. These are recorded calendar differences, not active FDA review time.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K221610 ↗ · this pageNextra CH Cannulated Hammertoe System2022-06-03 → 2022-11-04154Traditional
K262975 ↗Arthrex Beaming System2026-08-26 → 2026-09-2530Special
K260995 ↗DynaNail Helix® Fixation System2026-03-26 → 2026-09-23181Traditional
K254280 ↗F.A.S.T Screw2025-12-30 → 2026-09-21265Traditional
K261057 ↗ActivaScrew™ Cannulated COM2026-03-31 → 2026-09-04157Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 82 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K221610 · PDF page 3 ↗ Source 2

The Nextremity Solutions Nextra® CH Cannulated Hammertoe                    System is indicated for               small bone reconstruction limited
to inter-phalangeal repair and fusion of the lesser toes.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K221610 · PDF page 4 ↗ Source 3

The Nextra® CH Cannulated Hammertoe System consists of a two-part cannulated bone screw
implant construct. The screw implants are provided in various sizes. The proximal screw implant
diameters range from 2.75mm to 4.2mm.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K221610 · PDF page 5 ↗ Source 4

Endotoxin testing was performed using the Limulus Amebocyte Lysate (LAL) method according
to AAMI ST72, USP 161 and USP 85. Results met the Endotoxin limit of ≤20 EU per device.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK221610 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryNextra CH Cannulated Hammertoe System [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantNextremity Solutions, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeHWC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2022-11-04 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2022-06-03 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[87262] · record d9a7a518d666e5ae7ce8065e4a9cbd633bdb5199df7fb9b70a0c5fc0b890bb8b
  • [5] Complete results array / fda-decision-context:K221610 · record whole dataset partition

FDA 510(k) summary — K221610 ↗

Sat, 05 Nov 2022 21:02:02 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 54a7b718c3984252d5c12dc135564760e3f401b85a384b959e21af2f2b5e0553

  • [2] PDF page 3 · record eac5c4e8c17515d2ebbceec3cec50bc0b85ddda28022850c25302f99f26e043d
  • [3] PDF page 4 · record 221c760c4d67801880f795c43dfaafb18e34430c3858bcd532830ee39e54468c
  • [4] PDF page 5 · record 2724c877d299d778c521d63988ce1e366c7452ef7f426b21a4fbb5e2d321517a

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services